Drug developers looking to Xolair's example in a changing asthma market, study says

10 November 2016
2019_biotech_test_vial_discovery_big

Biologics and monoclonal antibodies (MAbs) will become a bigger presence within the asthma therapeutics market, according to a new report from business intelligence firm GBI Research.

The report notes that small molecules currently account for 98% of available products in this therapeutic space, but highlights that the asthma pipeline consists of 12% MAbs and 17% non-MAb biologics.

One of the few currently-marketed MAb asthma therapeutics is Xolair (omalizumab) from Roche (ROG: SIX) subsidiary Genentech, which reached blockbuster status in 2014. It is approved for adults and adolescents aged 12 and over, with moderate-to-severe allergic asthma and symptoms not adequately controlled with inhaled corticosteroids.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology